VN November 2020

Vetnews | November 2020 31 times less likely to develop a new intramammary infection. 4 Internal teat sealants were developed in an effort to protect the udder from ascending intramammary infections for the duration of the dry period, until it is milked out at the desired time. 3 Studies done in several countries, including the United Kingdom, Australia, New Zealand, the United States and Canada, have shown the benefits in the use of an internal teat sealant for the prevention of new intramammary infections and clinical mastitis in the following lactation. 1 Intramammary infections One meta-analysis found that risk of developing new intramammary infections after calvingwere reduced by 25%when using an internal teat sealant either by itself or in combination with antibiotic dry cow therapy, compared to using antibiotic dry cow therapy by itself. 1 Compared to untreated animals, use of an internal teat sealant reduced the risk of intramammary infections by 73%. 1 Putting the results of the studies together, the use of internal teat sealants (alone or in combination with an intramammary antibiotic) reduced the risk of intramammary infections by 39% when compared to animals not treated and those treated with an intramammary antibiotic alone. 1 Clinical mastitis The same meta-analysis mentioned above, also found beneficial results when using internal teat sealants to reduce the risk of clinical mastitis. The risk of clinical mastitis was reduced by 29%, when comparing the use of intramammary antibiotics only, with the use of internal teat sealants either by itself or in combination with an intramammary antibiotic in fresh cows. 1 When compared to animals not treated, an internal teat sealant reduced the risk of clinical mastitis by 48%. 1 Overall results showed a 34 % reduction in risk when using an internal teat sealant by itself or in combination with an intramammary antibiotic. 1 Another study also showed significant differences in the number of quarters affected by clinical mastitis during the early dry period, when comparing udders treated with antibiotics alone (25/40 quarters, 9.3%) vs those treated with a combination of antibiotics and an internal teat sealant (15/40 quarters, 5.6%). 3 Conclusion In conclusion, we can agree that there are many factors that play a role in udder health. It has been shown that herd management factors during the dry period such as hygiene, calving area, dry cow therapy etc. can have an influence on the rate of clinical mastitis cases in the next lactation. 3 Therefore, strategic management that is focused on the specific needs and challenges of each specific farm, is vital. As is evident from the host of research data available, the use of an appropriate intramammary dry cow antibiotic along with an internal teat sealant where needed, can likely reduce the incidence of clinical mastitis and intramammary infections during the following lactation. This will also most likely reduce the use of antibiotics during lactation, saving the producer the costs of treatment and milk discard. 3 Herds that will most possibly benefit from the use of an internal teat sealant, are those that suffer from clinical mastitis caused by environmental pathogens or herds with an extended dry period. 3 Contact Zoetis to learn more about Orbeseal ®, an internal teat sealant that can be used in dry cow therapy. v References: 1. Rabiee AR, Lean IJ. 2013.The effect of internal teat sealant products (Teatseal and Orbeseal) on intramammary infection, clinical mastitis, and somatic cell counts in lactating dairy cows: A meta-analysis. J. Dairy Sci 96:6915-6931. 2. Berry EA, Hillerton JE. 2007. Effect of an intramammary teat seal and dry cow antibiotic in relation to dry period length on postpartum mastitis. J. Dairy Sci 90:760-765. 3. M ü tze K, Wolter W, Failing K, Kloppert B, Bernhardt H, Zsch ö ck M. 2012.The effect of dry cow antibiotic with and without an internal teat sealant on udder health during the first 100 d of lactation: a field study with matched pairs. J. Dairy Sci 79:477-484. 4. Bradley AJ, Green MJ. 2004. The importance of the non- lactating period in the epidemiology of intra-mammary infection and strategies for prevention. Vet Clin Food Anim 20:547-568. FOR ANIMAL USE ONLY Orbeseal®. Reg. No.: G4174 (Act 36/1947). Each 4 g syringe contains an intramammary suspension with 65 % Bismuth Subnitrate. For full prescribing information refer to the package insert approved by the medicines regulatory authority. Full product information available from Zoetis South Africa (Pty) Ltd., Co. Reg. No.: 2012/001825/07, 6th Floor, North Wing, 90 Rivonia Road, Sandton, 2196. PostNet Suite 53, Private Bag 9976, Sandton, 2146. South Africa. Tel.: +27 11 245 3300 or 0860 ZOETIS (0860 963847). www.zoetis.co.za Reference No.: RU/CE/10/2020/12 Regulars I Zoetis pages

RkJQdWJsaXNoZXIy OTc5MDU=